AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

Reuters

Wed, April 29, 2026 astatine 6:50 AM CDT 2 min read

April 29 (Reuters) - AbbVie connected Wednesday reported better-than-expected quarterly gross and profit, fueled by request for newer immunology drugs Skyrizi and ‌Rinvoq, arsenic the drugmaker continues to navigate its modulation distant ‌from its once-blockbuster drug, Humira.

The institution has been leaning heavy connected Skyrizi and Rinvoq to ​fill the void near by Humira, which mislaid U.S. patent exclusivity successful 2023 and has since faced a question of cheaper biosimilar competition.

Last year, AbbVie said it expects the 2 drugs to bring successful much than $31 cardinal successful ‌combined income by 2027.

Skyrizi recorded ⁠sales of $4.48 cardinal for the archetypal quarter, increasing 30.9% from a twelvemonth earlier and beating Wall Street estimates of $4.41 ⁠billion, according to LSEG data. Rinvoq income grew 23.3% to $2.12 billion, besides topping estimates of $2.04 billion.

Global income of Humira fell 38.6% to $688 cardinal successful the ​quarter, somewhat ​missing analysts' anticipation of $696.5 million.

In January, ​the drugmaker struck a woody ‌with the Trump medication to little prices of definite medications including Humira, providing the institution with an exemption from tariffs and aboriginal pricing mandates.

Beyond immunology, AbbVie's neuroscience portfolio emerged arsenic a standout performer, with gross surging 26% to $2.88 billion. Its Global Botox Therapeutic crossed the $1 cardinal quarterly people for ‌the archetypal time, which was besides up ​of expectations of $996.5 million.

On an adjusted basis, ​the institution earned $2.65 per stock ​for the 4th ended March 31, supra analysts' expectations ‌of $2.59 per share.

Quarterly gross came successful astatine $15 ​billion, compared to ​analysts' estimation of $14.72 billion.

AbbVie besides raised its full-year adjusted net forecast to a scope of $14.08 to $14.28 per stock from $13.96 to $14.16. The forecast ​includes a 41 cent ‌per stock deed from acquired in-process R&D and milestone expenses booked ​through the archetypal quarter.

(Reporting by Kamal Choudhury and Christy Santhosh ​in Bengaluru; Editing by Maju Samuel)